Brain Cancer Clinical Trials in Illinois

Showing 201-210 of 210 trials

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

NCT00389090

This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.

GliomaAstrocytomaOligodendroglioma+1 more

Keryx / AOI Pharmaceuticals, Inc.32 participantsStarted Oct 2006

Los Angeles, California, United States • Orlando, Florida, United States • Chicago, Illinois, United States +9 more locations

TERMINATEDPhase 2125 miles

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00515086

This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)

Glioblastoma Multiforme

Novartis Pharmaceuticals41 participantsStarted Aug 2007

Los Angeles, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +5 more locations

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Brain Cancer Trials in Other Cities

Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Other Conditions in Illinois